Invasive lobular carcinoma cell lines are characterized by unique estrogen-mediated gene expression patterns and altered tamoxifen response

Cancer Research

Volumn 74, Issue 5, 2014, Pages 1463-1474

  Sikora, Matthew J ^a,c   Cooper, Kristine L ^d   Bahreini, Amir ^a   Luthra, Soumya ^b   Wang, Guoying ^f   Chandran, Uma R ^b   Davidson, Nancy E ^a,c   Dabbs, David J ^e   Welm, Alana L ^f   Oesterreich, Steffi ^a,c  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b Departments of Biomedical Informatics   (United States)

^c Departments of Pharmacology and Chemical Biology   (United States)

^d Biostatistics ^*  (United States)

^e UNIVERSITY OF PITTSBURGH   (United States)

^f UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 1; TAMOXIFEN; TRANSCRIPTOME;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER RESISTANCE; CASE REPORT; CELL VIABILITY; CHROMATIN IMMUNOPRECIPITATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG TARGETING; FEMALE; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; HORMONE RELEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; MICROARRAY ANALYSIS; MIDDLE AGED; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CARCINOMA, LOBULAR; CELL LINE, TUMOR; ESTROGENS; FEMALE; GENE EXPRESSION; HUMANS; MCF-7 CELLS; MIDDLE AGED; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION; TAMOXIFEN;

EID: 84896502580     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-2779     Document Type: Article

References (48)

1. Fisher ER, Gregorio RM, Fisher B, Redmond C, Vellios F, Sommers SC, et al. The pathology of invasive breast cancer. A syllabus derived from findings of the National Surgical Adjuvant Breast Project (protocol no. 4). Cancer 1975;36:1-85.
2. Cristofanilli M, Gonzalez-Angulo A, Sneige N, Kau S-W, Broglio K, Theriault RL, et al. Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J Clin Oncol. 2005;23: 41-8.
3. Pestalozzi BC, Zahrieh D, Mallon E, Gusterson BA, Price KN, Gelber RD, et al. Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 international breast cancer study group clinical trials. J Clin Oncol 2008;26: 3006-14.
4. Arpino G, Bardou VJ, Clark GM, Elledge RM. Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res 2004;6:R149-56.
5. Sikora MJ, Jankowitz RC, Dabbs DJ, Oesterreich S. Invasive lobular carcinoma of the breast: patient response to systemic endocrine therapy and hormone response in model systems. Steroids 2013;78: 568-75.
6. Biglia N, Mariani L, Sgro L, Mininanni P, Moggio G, Sismondi P, et al. Increased incidence of lobular breast cancer in women treated with hormone replacement therapy: implications for diagnosis, surgical and medical treatment. Endocr Relat Cancer 2007;14:549-67.
7. Wasif N, Maggard MA, Ko CY, Giuliano AE. Invasive lobular vs ductal breast cancer: a stage-matched comparison of outcomes. Ann Surg Oncol 2010;17:1862-9.
8. Colleoni M, Rotmensz N, Maisonneuve P, Mastropasqua MG, Luini A, Veronesi P, et al. Outcome of special types of luminal breast cancer. Ann Oncol 2012;23:1428-36.
9. Rakha EA, El-Sayed ME,Powe DG, Green AR, Habashy H, Grainge MJ, et al. Invasive lobular carcinoma of the breast: response to hormonal therapy and outcomes. Eur J Cancer 2008;44:73-83.
10. Mhuircheartaigh JN, Curran C, Hennessy E, Kerin MJ. Prospective matched-pair comparison of outcome after treatment for lobular and ductal breast carcinoma. Br J Surg 2008;95:827-33.
11. Korhonen T, Kuukasj̈arvi T, Huhtala H, Alarmo E-L, Holli K, Kallioniemi A, et al. The impact of lobular and ductal breast cancer histology on the metastatic behavior and long term survival of breast cancer patients. Breast 2013;22:1119-24.
12. Metzger-Filho O, Giobbie-Hurder A, Mallon E, Viale G, Winer E, Thurlimann B, et al. Relative effectiveness of letrozole compared with tamoxifen for patients with lobular carcinoma in the BIG 1-98 trial. Cancer Res 2012;72:S1-1.
13. Riggins RB, Lan JP-J, Zhu Y, Klimach U, Zwart A, Cavalli LR, et al. ERRgamma mediates tamoxifen resistance in novel models of invasive lobular breast cancer. Cancer Res 2008;68:8908-17.
14. Reis-Filho JS, Simpson PT, Turner NC, Lambros MB, Jones C, Mackay A, et al. FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas. Clin Cancer Res 2006;12:6652-62.
15. Reiner GC, Katzenellenbogen BS. Characterization of estrogen and progesterone receptors and the dissociated regulation of growth and progesterone receptor stimulation by estrogen in MDA-MB-134 human breast cancer cells. Cancer Res 1986;46:1124-31.
16. Sikora MJ, Strumba V, Lippman ME, Johnson MD, Rae JM. Mechanisms of estrogen-independent breast cancer growth driven by low estrogen concentrations are unique versus complete estrogen deprivation. Breast Cancer Res Treat 2012;134:1027-39.
17. Ethier SP, Mahacek ML, Gullick WJ, Frank TS, Weber BL. Differential isolation of normal luminal mammary epithelial cells and breast cancer cells from primary and metastatic sites using selective media. Cancer Res 1993;53:627-35.
18. Ochsner S, Steffen DL, Hilsenbeck SG, Chen ES, Watkins C, McKenna NJ, et al.GEMS(Gene Expression MetaSignatures), a web resource for querying meta-Analysis of expression microarray datasets: 17betaestradiol in MCF-7 cells. Cancer Res 2009;69:23-6.
19. Creighton CJ, Cordero KE, Larios JM, Miller RS, Johnson MD, Chinnaiyan AM, et al. Genes regulated by estrogen in breast tumor cells in vitro are similarly regulated in vivo in tumor xenografts and human breast tumors. Genome Biol 2006;7:R28.
20. Schmidt D, Wilson MD, Spyrou C, Brown GD, Hadfield J, Odom DT, et al. ChIP-seq: using high-Throughput sequencing to discover protein-DNA interactions. Methods 2009;48:240-8.
21. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009;25:1754-60.
22. Zhang Y, Liu T, Meyer CA, Eeckhoute J, Johnson DS, Bernstein BE, et al. Model-based analysis of ChIP-Seq (MACS). GenomeBiol 2008;9: R137.
23. Shin H, Liu T, Manrai AK, Liu XS. CEAS: cis-regulatory element annotation system. Bioinformatics 2009;25:2605-6.
24. Quinlan AR, Hall IM. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics 2010;26:841-2.
25. Joseph R, Orlov YL, Huss M, Sun W, Kong SL, Ukil L, et al. Integrative model of genomic factors for determining binding site selection by estrogen receptor-A. Mol Syst Biol 2010;6:456.
26. Ross-Innes CS, Stark R, Holmes KA, Schmidt D, Spyrou C, Russell R, et al. Cooperative interaction between retinoic acid receptor-Alpha and estrogen receptor in breast cancer. Genes Dev 2010;24:171-82.
27. Ross-Innes CS, Stark R, Teschendorff AE, Holmes K A., Ali HR, Dunning MJ, et al. Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature 2012;481: 389-93.
28. Schmidt D, Schwalie PC, Ross-Innes CS, Hurtado A, Brown GD, Carroll JS, et al.ACTCF-independent role for cohesin in tissue-specific transcription. Genome Res 2010;20:578-88.
29. Tsai W-W, Wang Z, Yiu TT, Akdemir KC, Xia W, Winter S, et al. TRIM24 links a non-canonical histone signature to breast cancer. Nature 2010; 468:927-32.
30. DeRose YS,WangG, Lin Y-C, BernardPS, BuysSS, EbbertMTW,et al. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat Med 2011;17:1514-20.
31. DeRose YS, Gligorich KM, Wang G, Georgelas A, Bowman P, Courdy SJ, et al. Patient-derived models of human breast cancer: protocols for in vitro and in vivo applications in tumor biology and translational medicine. Curr Protoc Pharmacol 2013;60:14.23.1-14.23.43.
32. Saeed AI, Sharov V, White J, Li J, Liang W, Bhagabati N, et al. TM4: a free, open-source system for microarray data management and analysis. Biotechniques 2003;34:374-8.
33. Hurtado A, Holmes KA, Ross-Innes CS, Schmidt D, Carroll JS. FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nat Genet 2011;43:27-33.
34. Bryant HU. Selective estrogen receptor modulators. Rev Endocr Metab Disord 2002;3:231-41.
35. Turner N, Pearson A, Sharpe R, Lambros M, Geyer F, Lopez-Garcia MA, et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res 2010;70:2085-94.
36. Derksen PWB, Liu X, Saridin F, van der Gulden H, Zevenhoven J, Evers B, et al. Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis. Cancer Cell 2006;10:437-49.
37. Bertucci F, Orsetti B, Negre V, Finetti P, Rouge C, Ahomadegbe J-CC, et al. Lobular and ductal carcinomas of the breast have distinct genomic and expression profiles. Oncogene 2008;27:5359-72.
38. Weigelt B, Horlings HM, Kreike B, Hayes MM, Hauptmann M, Wessels LFA, et al. Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol 2008;216:141-50.
39. Weigelt B, Geyer FC, Natrajan R, Lopez-Garcia MA, Ahmad AS, Savage K, et al. The molecular underpinning of lobular histological growth pattern: a genome-wide transcriptomic analysis of invasive lobular carcinomas and grade-And molecular subtype-matched invasive ductal carcinomas of no special type. J Pathol 2010;220:45-57.
40. Dabbs DJ, Bhargava R, Chivukula M. Lobular versus ductal breast neoplasms: the diagnostic utility of p120 catenin. Am J Surg Pathol 2007;31:427-37.
41. Oesterreich S, Deng W, Jiang S, Cui X, Ivanova M, Schiff R, et al. Estrogen-mediated down-regulation of E-cadherin in breast cancer cells. Cancer Res 2003;63:5203-8.
42. Ross JS, Wang K, Sheehan CE, Boguniewicz AB, Otto G, Downing SR, et al. Relapsed classic E-cadherin (CDH1)-mutated invasive lobular breast cancer shows a high frequency of HER2 (ERBB2) gene mutations. Clin Cancer Res 2013;19:2668-76.
43. Brunello E, Brunelli M, Bogina G, Calio A, Manfrin E, Nottegar A, et al. FGFR-1 amplification in metastatic lymph-nodal and haematogenous lobular breast carcinoma. J Exp Clin Cancer Res 2012;31:103.
44. Brisken C, Heineman A, Chavarria T, Elenbaas B, Tan J, Dey SK, et al. Essential function of Wnt-4 in mammary gland development downstream of progesterone signaling. Genes Dev 2000;14:650-4.
45. Droog M, Beelen K, Linn S, Zwart W. Tamoxifen resistance: From bench to bedside. Eur J Pharmacol 2013;717:47-57.
46. McBryan J, Theissen SM, Byrne C, Hughes E, Cocchiglia S, Sande S, et al. Metastatic progression with resistance to aromatase inhibitors is driven by the steroid receptor coactivator SRC-1. Cancer Res. 2012; 72:548-59.
47. Graham JD, Bain DL, Richer JK, Jackson TA, Tung L, Horwitz KB, et al. Thoughts on tamoxifen resistant breast cancer. Are coregulators the answer or just a red herring? J Steroid Biochem Mol Biol 2000;74: 255-9.
48. Hsu P-Y, Hsu H-K, Lan X, Juan L, Yan PS, Labanowska J, et al. Amplification of distant estrogen response elements deregulates target genes associated with tamoxifen resistance in breast cancer. Cancer Cell 2013;24:197-212.